Mutual of America Capital Management LLC Has $2.29 Million Holdings in Insulet Co. (NASDAQ:PODD)

Mutual of America Capital Management LLC lessened its position in Insulet Co. (NASDAQ:PODD) by 5.0% in the 4th quarter, Holdings Channel reports. The fund owned 10,565 shares of the medical instruments supplier’s stock after selling 561 shares during the period. Mutual of America Capital Management LLC’s holdings in Insulet were worth $2,292,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Insulet by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 6,203,941 shares of the medical instruments supplier’s stock worth $1,652,668,000 after acquiring an additional 58,932 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of Insulet by 38.8% during the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after purchasing an additional 474,545 shares during the period. Geode Capital Management LLC grew its position in Insulet by 55.4% during the first quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock valued at $473,166,000 after purchasing an additional 529,926 shares in the last quarter. Moneta Group Investment Advisors LLC increased its stake in Insulet by 101,333.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock valued at $382,818,000 after buying an additional 1,299,095 shares during the period. Finally, Baillie Gifford & Co. acquired a new position in Insulet in the 4th quarter valued at approximately $263,144,000.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research reports. Piper Sandler decreased their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. JPMorgan Chase & Co. lifted their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Barclays dropped their target price on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Finally, Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Stock Up 0.9 %

PODD opened at $166.25 on Friday. The firm has a market cap of $11.64 billion, a P/E ratio of 57.13, a price-to-earnings-growth ratio of 2.97 and a beta of 0.98. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The business has a 50 day moving average price of $173.97 and a 200 day moving average price of $178.96. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. During the same period in the previous year, the company earned $0.55 earnings per share. Insulet’s revenue for the quarter was up 37.9% on a year-over-year basis. Research analysts forecast that Insulet Co. will post 3.08 EPS for the current year.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.90% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.